retatrutide phase 2 trial type 2 diabetes weight loss 2024 Lilly's triple agonist delivers up to 71.2 lbs of Advancements in Clinical Research and

Sources Eli Lilly press release TRIUMPH-1 Phase 3 topline results, May 21, 2026 Eli Lilly press release TRIUMPH-4 Phase 3 trial results, December 2025 Eli Lilly press release TRANSCEND-T2D-1 topline results, March 19, 2026 Bajaj HS et al

The total weekly dose remains 8mg, but the peak plasma concentration is lower, which reduces GI symptoms for many researchers

Small Lumps or Firmness Some people notice small lumps, called nodules, or a thickening of the skin around the area where they inject their GLP-1

Progress often accelerates at this dose

Microdosing means using well-below-standard starting doses of a GLP1 agonist to gain metabolic and neurologic benefits while minimizing side effects

Who should avoid retatrutide due to safety concerns